Intel stock spikes after report of possible US government stake
Investing.com - Citizens JMP analyst Roy Buchanan raised the price target on Enanta Pharmaceuticals (NASDAQ:ENTA) to $25.00 from $24.00 while maintaining a Market Outperform rating. According to InvestingPro data, the stock currently trades at $6.49, with analyst targets ranging from $7 to $24, suggesting significant potential upside despite recent market pressure.
Enanta reported fiscal third-quarter 2025 results that exceeded both analyst and consensus expectations, driven by strong revenues and continued expense reductions.
The company ended the quarter with $204 million in cash and provided guidance that its cash position and continuing Mavyret income would fund operations into fiscal 2028.
Enanta’s next major clinical catalyst will be Phase 2 results for zelicapavir, its oral N-protein inhibitor for RSV in high-risk adults, expected next month. Management is targeting approximately a one-day improvement in symptom resolution compared to placebo.
The company continues to develop its immunology pipeline and plans to announce a third program in 2025, according to Citizens JMP’s research note.
In other recent news, Enanta Pharmaceuticals announced the U.S. Food and Drug Administration’s approval of MAVYRET as an eight-week treatment for acute hepatitis C, achieving a 96% cure rate in clinical trials. This approval broadens the treatment’s indication to include both acute and chronic hepatitis C in adults and children three years and older. Enanta also reported its second-quarter fiscal year 2025 results, ending the quarter with a cash reserve of $193 million and projecting financial stability through fiscal year 2028. In analyst updates, H.C. Wainwright initiated coverage on Enanta Pharmaceuticals with a Buy rating and a $20 price target, citing a favorable risk-reward profile. Additionally, Citizens JMP raised its stock price target for Enanta to $24, maintaining a Market Outperform rating, while JMP analysts increased their target to $23, also with a Market Outperform rating. Enanta’s focus on immunology and the anticipated results of its mid-stage RSV trial were noted as key factors in these assessments. The company plans to present data from its Phase 2 study of the RSV drug zelicapavir at the ESPID 2025 conference, highlighting the drug’s efficacy in pediatric patients. However, further development of this candidate may require a partnership, as indicated by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.